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Abstract
Objective: Cardiovascular risk increases with the presence of both metabolic syndrome (MetS) and hypertension (HTN).
Although the adiponectin (ADIPOQ) gene has been reported to be involved in MetS, its association with HTN remained
undetermined. This study aimed to investigate the association of ADIPOQ gene with the phenotypes of HTN and MetS.
Methods: A total of 962 participants from 302 families from the Taiwan young-onset hypertension genetic study were
enrolled. Plasma adiponectin were measured, and association analysis was conducted by using GEE regression-based
method. Another study, of 1448 unrelated participants, was conducted to replicate the association between ADIPOQ gene
and variable phenotypes of MetS with or without HTN.
Results: Among 962 subjects from family samples, the lowest plasma adiponectin value was observed in MetS with HTN
component (9.360.47 mg/ml) compared with hypertensives (13.460.74 mg /ml) or MetS without HTN (11.960.60 mg/ml,
P,0.05). The SNP rs1501299 (G276T) in ADIPOQ gene was found associated with the presence of HTN in MetS (odds ratio for
GG+GT vs. TT=2.46; 95% CI: 1.14-5.3, p=0.02), but not rs2241766 (T45G). No association of ADIPOQ gene with HTN alone or
MetS without HTN was observed. The significant association of the SNP rs1501299 (G276T) with the phenotype of presence
of HTN in MetS was confirmed (odds ratio for GG+GT vs. TT=2.15; 95% CI: 1.1–4.3) in the replication study.
Conclusions: ADIPOQ genetic variants were selectively and specifically associated with the concomitant presence of MetS
and HTN, suggesting potential genetic linkage between MetS and HTN.
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Introduction
It is suggested that metabolic syndrome (MetS), the presence of
various metabolic and cardiovascular risk factors including insulin
resistance, glucose intolerance, central obesity, elevated blood
pressure, and dyslipidemia, may lead to poor clinical outcomes
with increased cardiovascular morbidity and early death [1,2].
However, not all components of MetS contribute equally to the
risk. Hypertension (HTN), rather than other risk factors, has been
reported to be independently associated with an increased
cardiovascular risk in subjects with MetS [3]. Hypertensive
patients with MetS have double the cardiovascular risk compared
to those without [4]. Thus, the presence of hypertension
components of MetS might imply a potential clinical sub-
phenotype with higher risk. However, it was not known whether
there is pathophysiological and genetic background contributing to
the HTN component of MetS. Previous studies which investigated
the heritability of MetS demonstrated there were two independent
clusters of composing factors in MetS – lipids, glucose, and obesity
in one group and blood pressure alone in another group,
suggesting possible distinct genetic background for MetS contain-
ing HTN component [5]. Recently, with genome-wide scanning,
several novel genetic loci have been found related to the clinical
presentation of MetS in different populations [6,7], but the genetic
linkage between essential hypertension and MetS remained
undetermined.
Adiponectin is an adipose tissue-derived cytokine with anti-
inflammatory and anti-atherogenic properties which was linked to
central obesity and proposed as major contributor to MetS in
addition to insulin resistance [8]. Reduced plasma adiponectin
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19999levels were observed in patients with obesity, diabetes, and
coronary artery disease [9]. Though the presence of MetS has
been linked to decreased plasma adiponectin values, the role of
adiponectin (ADIPOQ) gene in determining MetS components
especially HTN [9], remained undetermined [10]. Furthermore,
reduced plasma adiponectin level was observed among young
healthy participants with hypertensive parents [11], suggesting
genetic association with ADIPOQ may contribute to the phenotype
of HTN. In addition to clinical observation, knockout mice lacking
ADIPOQ gene also exhibited HTN, hypertriglyceridemia, and
hyperglycemia, the features of MetS [12]. Taken all together, this
evidence implies it is possible that the ADIPOQ gene might be
linked to the presence of MetS and HTN. The present study was
conducted to investigate whether ADIPOQ genetic variants are
associated with the phenotype of the presence of HTN among
MetS. This study was conducted by a family-based approach, and
subsequently verified by another independent sample.
Methods
Subjects and phenotype definition
Family-based association study. Study subjects from the
familyassociationstudywereenrolledfromthe Taiwanyoung-onset
hypertension genetic study [13] and young hypertension probands
were identified from four community hospitals located in northwest
Taiwan. For each identified proband, family members including
their parents, affected or unaffected sib pairs were invited for a BP
screening and enrolled into this study. The family structure
comprised two generations and was a nuclear-family format. A
total of 962 subjects, 495 men and 467 women from 302 nuclear
families, were enrolled in this study. Both parents of probands were
recruited in 23.1% of the families, and one parent in 27.2% of the
families. Four distinct phenotypes, of (1) normotensive and non-
metabolic syndrome; (2) HTN without MetS; (3) MetS with HTN,
and (4) MetS without HTN, were clearly identified in this family
association study database (Figure 1). The diagnosis of HTN was
defined as systolic blood pressure .140 mmHg and/or diastolic
blood pressure .90 mmHg or currently taking at least one
antihypertensive medication. Exclusion criteria were the presence
of any of secondary causes of hypertension such as chronic renal
disease,renal arterialstenosis,primaryaldosteronism,coarctation of
the aorta, thyroid disorders, Cushing syndrome, and pheochr-
omocytoma through extensive clinical examinations and
investigations (including blood chemistry, renal function tests,
endocrine examination, and abdominal sonogram). Participants
who fulfilled at least three of the following five criteria of MetS were
defined as ‘‘affected’’ status for MetS according to the ATPIII
criteria. The five criteria included (1) blood pressure $ 130/
85 mmHg, (2) fasting plasma glucose level .110 mg/dL, (3)
hypertriglyceridemia with triglyceride level $150 mg/dL, (4)
high-density lipoprotein-cholesterol (HDL-C) level ,1.0 mmol/l
in men or ,1.3 mmol/l in women, and (5) central obesity with
waist circumference .90 cm in men or .80 cm in women. The
definition of central obesity has been modified for the Asian
population [14]. Participants were divided into variable phenotypes
of HTN and MetS.
Replication study. In order to replicate the finding found in
the family-based study, we conducted another study including 1448
unrelated subjects without cardiovascular events to confirm the
above study’ results. The replication study included an unrelated
706 males and 742 females, who were grouped into subtypes of
HTN and MetS according to the above family based association
study design. The study cohort was selected from the Cardio-
Vascular Disease risk FACtors Two-township Study (CVDFACTS)
[15,16]. Briefly, the CVDFACTS was a community-based follow-
up study investigating the cardiovascular disease occurrence and
risk factors in Taiwan since 1989. Five villages with more than 1000
people and population density greater than 200 people per square
kilometer were randomly selected from Chu-Dong (northwest
Taiwan) and Pu-Tzu (southwest Taiwan) areas. Information about
participants’ lifestyle, risk factors, history of cardiovascular disease,
urine and blood chemistry data was collected. The study protocol
was approved by the Human Investigation Committee of the
Institute of Biochemical Science, Academia Sinca, Taiwan, and all
subjects gave written informed consent.
DNA preparation and genotyping
Blood pressure, pulse, height, and weight were measured
according to the standardized protocol established for the
Nutrition and Health Survey in Taiwan [17]. Forearm venous
blood samples were drawn from each patient or participant by
venipuncture after an overnight fast of 10–12 hours. The buffy
coat (the white cell layer) was pipetted into a vial and frozen at
270uC. Genomic DNA of the probands and their relatives
were isolated from collected peripheral lymphocytes by the
phenol/chloroform extraction method. The reason why we
selected these three SNPs is that based on previous findings.
The two SNP markers rs2241766 (T45G) and rs15011299
(G276T), are the common informative SNP markers in Asian
populations. Although many SNP markers in ADIPOQ have
been studied, rs2241766 (T45G) and rs15011299 (G276T) were
reported to have a strong association with MetS in Japanese
population [18]. Furthermore, they are especially considered
for the MetS-associated ADIPOQ SNPs in Asian people among
five different populations [19]. In addition to SNPs rs2241766
(T45G) and rs15011299 (G276T), SNP (I164T) [20] has been
found to be associated with MetS and coronary artery disease
in Japanese population. Therefore, after considering the Asian
origin of our study population, these three SNPs were selected
f o rg e n o t y p i n gt ot e s tt he association between ADIPOQ gene
and phenotypes in the current study. The primary genotyping
technique was TaqMan SNP allelic discrimination using an
Figure 1. The compositions of the study subjects in both family
association study and case-control study, which included 1,
sub-phenotype 1, the subjects with neither hypertension nor
metabolic syndrome; 2, sub-phenotype 2, the subjects with
hypertension but no metabolic syndrome; 3, sub-phenotype 3,
the subjects with both hypertension and metabolic syndrome;
4, sub-phenotype 4, the subjects with metabolic syndrome but
no hypertension.
doi:10.1371/journal.pone.0019999.g001
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previously described.
Measurement of metabolic profiles and plasma
adiponectin level
Metabolic profiles, including total cholesterol, HDL-C, triglyc-
eride, and other biochemical parameters were measured using a
Hitachi 7600-310 autoanalyzer (Hitachi Ltd., Tokyo, Japan).
Plasma concentration of high-molecular-weight adiponectin were
determined by a sandwich enzyme-linked immunosorbent assay
system (Otsuka Pharmaceutical Co., Tokushima, Japan) as
described previously [21].
Statistical analysis
All data were expressed as mean 6 SEM if normally distributed
or as median (range) otherwise. Parametric continuous data
between groups were compared by an unpaired Student’s t-test
and ANOVA test. Categorical data between groups were compared
with the chi-square test or Fisher’s exact test. The comparisons of
genetic association with ADIPOQ variants were used to evaluate the
association of the presence of each phenotype compared with the
remaining subjects and ADIPOQ SNP markers. Because family
members are not independent with respect to each other, family
structure was adjusted using a generalized estimating equation
(GEE) (GEE model, Proc GENMOD using SAS statistical software)
[22], taking into account familial dependence of the observations to
estimate the association of ADIPOQ genetic variant between these
distinct phenotypes of HTN and MetS. Parameters including age,
sex, body mass index, glucose, waist circumference, total cholester-
ol, triglycerides and HDL-C were added for adjustment. In
addition, the association of MetS parameters and ADIPOQ SNP
were assessed by linear regression to determine the genetic
association of ADIPOQ variants and quantitative traits of MetS.
To verify the association between ADIPOQ SNP and
phenotypes, we utilized data from the independent cohort study
to perform regression analysis on SNPs in the ADIPOQ gene with
respect to variable phenotypes of interest. Age, gender, blood
pressure, and metabolic profiles were included as covariates.
Parametric continuous data between groups were compared by
unpaired Student’s t-test and ANOVA test. Categorical data
between groups were compared with the chi-square test or Fisher’s
exact test. In the family association study, G allele of rs15101299
(G276T) of the ADIPOQ gene was significantly associated with the
phenotype of metabolic syndrome with HTN component under
Table 1. Baseline characteristics of all family subjects.
MetS (2) MetS (+)
Trait
HTN (2)
(n=446)
HTN (+)
(n=159)
HTN (2)
(n=165)
HTN(+)
(n=192)
Age, years 46.760.8{{1 41.460.7*{ 57.561.0*{1 41.760.6*{
Male, n (%) 215 (49) 90 (57) 65(39) 125 (65)
BMI, kg/m
2 23.560.1{{1 25.460.3*{1 27.160.3*{1 28.360.3*{{
Waist circumference, cm 7960.5{{1 83.160.7*{1 90.460.7*{ 92.960.6*{
Blood pressure, mmHg
Systolic 119.460.8{{1 140.361.5* 137.761.4* 140.161.4*
Diastolic 74.360.6{{1 89. 61.0*{1 83.360.9*{1 90.561.0*{{
Metabolic profiles
Cholesterol, mg/dl 192.962.0{1 195.763.1{1 209.563.5*{ 215.563.9*{
HDL-C, mg/dl 53.96.7{1 52.260.9{1 42.060.8*{ 41.160.7*{
LDL-C, mg/dl 119.861.8 125.662.9 122.763.1 127.763.4
Triglycerides, mg/dl 110.963.4{1 116.565.5{{ 235.4611.1*{ 241.3612.2*{
Glucose, mg/dl 96.761.3{1 98.261.4{1 142.966.9*{1 127.464.5*{{
Adiponectin, mg/ml 15.960.5{{1 11.960.6*1 13.460.7*1 9.360.5*{{
ADIPOQ genotype
rs1501299 (G276T)
TT, n (%) 40 (8.9) 14 (8.8) 16 (9.8) 7 (3.8)
GT, n (%) 178 (39.9) 60 (37.7) 56 (33.7) 68 (35.6)
GG, n (%) 228 (51.1) 85 (53.4) 93 (56.4) 117 (60.6)
rs2241766 (T45G)
GG, n (%) 32 (7.2) 15 (9.4) 12 (7.2) 19 (9.9)
TG, n (%) 181 (40.6) 70 (44) 75 (45.5) 81 (42.1)
TT, n (%) 233 (52.2) 74 (46.5) 78 (47.3) 92 (47.9)
Data are mean 6 SEM or number (%); HTN indicates hypertension; MetS, metabolic syndrome; BMI, indicates body mass index; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol.
*P, 0.001 vs.MetS(-)HTN(2);
{P, 0.001 vs. MetS(+)HTN(2);
{P, 0.001 vs. MetS(2)HTN(+);
1P, 0.001 vs. MetS(+)HTN(+).
doi:10.1371/journal.pone.0019999.t001
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genetic association of distinct phenotype compared with other
remaining subjects using TT genotype as a referent. All these
statistical analysis were performed using SAS for Window software
(version 9.1).
Results
Basic characteristics of the family study participants
A comparison of characteristics of variable phenotypes of MetS
with or without HTN in the young-onset HTN families is shown in
Table 1. Compared with the normotensive participants, hyper-
tensive participants had significantly higher blood pressure, larger
BMI, and increased waist circumference. Furthermore, hyperten-
sive subjects had higher serum triglyceride and cholesterol levels,
and lower HDL-C and adiponectin levels, than the normotensive
participants. Among 962 subjects from family samples, the lowest
plasma adiponectin value was observed in MetS with HTN
component (9.360.47 mg/ml) compared with that in hyperten-
sives (13.460.74 mg/ml) or MetS without HTN (11.960.60 mg/
ml, P,0.05). The association was still significant after adjustment
for metabolic profiles and BMI, and was also consistent in both
men and women when analyzed separately.
SNP polymorphisms of adiponectin gene in study
population
Among the three SNP markers of the adiponectin gene used in
the young-onset HTN family study, the I164T polymorphism,
which was previously reported in the Japanese population, was not
found to be informative in our study participants. In our study
subjects, the minor allele frequencies of rs2241766 (T45G) T.G
and rs1501299 (G276T) G.T were 29.2% and 27.2%, respec-
tively. Allele frequencies of both markers did not show any
significant deviation from those expected according to Hardy-
Weinberg equilibrium in either population. Only the SNP
rs1501299 (G276T) was found associated with the presence of
HTN in MetS after adjusting for age gender, waist circumference
and metabolic profile using a GEE analysis under a dominant
model (odds ratio for GG+GT vs. TT=2.46; 95% CI: 1.14-5.3,
p=0.02) (Table 2). No association of ADIPOQ with merely HTN
or MetS without hypertension was observed. Table 3 shows the
regression analysis of individual components and plasma adipo-
nectin value, and ADIPOQ gene variants. There was no significant
association between ADIPOQ genotypes and plasma adiponectin
values as well as MetS parameters in our study.
Replication of the association between ADIPOQ and the
concomitant presence of HTN and MetS in case-control
study
In the subsequent verification study with 1448 unrelated
subjects (Table 4), the association of G allele of ADIOPQ SNP
Table 2. GEE analysis for association of adiponecin variant
and trait in variable phenotypes of hypertension and
metabolic syndrome among family subjects.
Phenotype Genotype OR (95%CI)
aMetS(-) HTN(-)
rs1501299 (G276T) TT 1
GT 0.87 (0.51–1.47)
GG 0.66 (0.4–1.11
TT 1
GG+GT 0.74 (0.45–1.22)
rs2241766 (T45G) GG 1
TG 0.91 (0.53–1.55)
TT 1.05 (0.62–1.79)
GG 1
TT+TG 0.98 (0.59–1.64)
bMetS (2) HTN (+)
rs1501299 (G276T) TT 1
GT 0.90 (0.47–1.74)
GG 0.93 (0.49–1.75)
TT 1
GG+GT 0.92 (0.49–1.7)
rs2241766 (T45G) GG 1
TG 0.87 (0.46–1.68)
TT 0.78 (0.41–1.49)
GG 1
TT+TG 0.82 (0.44–1.53)
cMetS (+) HTN (2)
rs1501299 (G276T) TT 1
GT 0.70 (0.35–1.43)
GG 0.9 (0.46–1.78)
TT 1
GG+GT 0.82 (0.42–1.59)
rs2241766 (T45G) GG 1
TG 1.62 (0.73–3.6)
TT 1.47 (0.67–3.26)
GG 1
TT+TG 1.54 (0.71–3.33)
dMetS(+) HTN (+)
rs1501299 (G276T) TT 1
GT 2.11 (0.95–4.7)
GG 2.74 (1.25–5.98)*
TT 1
GG+GT 2.46 (1.14–5.3)*
rs2241766 (T45G) GG 1
TG 0.89 (0.48–1.65)
TT 0.90 (0.79–1.65)
GG 1
TT+TG 1.45 (0.93–2.06)
All estimates were analyzed using generalized estimating equation (GEE) model
adjusted for age, sex, body mass index, glucose, blood pressure, waist
circumference, triglycerides, and HDL-choleserol.
*p,0.05 adjusting for age and gender. HTN indicates hypertension; MetS,
metabolic syndrome.
aIf the presence of phenotype of MetS(2)HTN(2) compared with other
remaining subjects.
bIf the presence of phenotype of MetS(2)HTN(+) compared with other
remaining subjects.
cIf the presence of phenotype of MetS(+)HTN(2) compared with other
remaining subjects.
dIf the presence of phenotype of (+)HTN(+) compared with other remaining
subjects.
doi:10.1371/journal.pone.0019999.t002
Table 2. Cont.
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family cohort was confirmed (odds ratio for GG+GT vs. TT: 2.15;
95% CI: 1.1–4.3) (Table 5). There was no association of ADIPOQ
genetic variant with HTN alone or with MetS without HTN.
Therefore, rs1501299 (G276T) polymorphism of ADIPOQ gene
may play a significant role in the genetic connection between
HTN and MetS (Table 5).
Discussion
Different from the previous studies regarding the genetics of
MetS as a whole, the present study is the first one to demonstrate
the association of ADIPOQ gene rs1501299 (G276T) mutation with
the concomitant presence of MetS and HTN. Such association
could not be seen in subjects with HTN alone or in normotensive
subjects with MetS, suggesting a selective genetic linkage of
ADIPOQ gene between MetS and essential HTN. HTN and MetS
might overlap partially with each other as a specific clinical sub-
phenotype with common genetic background.
Our current findings especially elucidate the genetic back-
ground of subjects of MetS with HTN, which is different from and
could not be applied to all the patients with MetS or HTN.
Although adiponectin is considered linked to MetS, a study with
genotyping 53 SNPs of the ADIPOQ gene failed to find any
correlation between ADIPOQ genetic variants and parameters of
MetS, suggesting the limited impacts of the ADIPOQ gene on
individual parameters of MetS [10]. Recently, a genome wide
association study (GWAS) showed no association between plasma
adiponectin and genetic loci associated with MetS parameters,
suggesting genetically determined adiponectin probably does not
modulate MetS directly [23]. Actually, previous clinical observa-
tion demonstrated that MetS could be dissected into two major
components: glucose/obesity/lipid as one cluster, and blood
pressure as the other one [5,24]. Subsequent heritability studies
of MetS also showed these two groups, lipid/glucose/obesity and
high blood pressure, significantly contributed the genetic back-
ground of MetS [5,25], indicating the heterogeneous nature of
MetS and possible different distinct pathogenesis between MetS
with and without HTN [5]. Our current study demonstrated
ADIPOQ associated with MetS with HTN component instead of
HTN alone or metabolic MetS without HTN component,
suggesting that MetS should be seen as clusters of metabolic
abnormalities and ADIPOQ may contribute genetically in some
clusters of MetS. This could explain why there was inconsistent
association observed between ADIPOQ and individual MetS
parameters in previous studies, and help to clarify previous
observations on the connection of ADIPOQ with MetS. Future
study is indicated to investigate the individual genetic background
and clinical significance in different subtypes of MetS rather than
in MetS as a whole.
Although more than 25 different genes have been identified to
connect to essential HTN either by linkage or association studies,
the replication studies have not shown consistent associations [26].
The WTCCC GWAS also failed to define any genetic signal
associated with HTN, indicating heterogeneity in the nature of
HTN [27]. Therefore, searching for clinically relevant subtypes of
HTN such as the concomitant presence of MetS and HTN may be
mandatory to dissect this complex disease. In the current study, we
demonstrated the association of favoring G allele of rs1501299
(G276T) polymorphism with the presence of HTN in MetS.
Table 3. Associations between MetS trait and ADIPOQ genetic variants.
rs1501299 (G276T)
Risk allele
(Genotypes) b(P)
GG TG TT G(G/T) Model 1
a Model 2
b Model 3
c
HDL-C, mg/dl 48.6660.622 49.2660.735 49.5961.197 21.599(0.09) 24.712(0.36) 21.267(0.294)
Glucose, mg/dl 109.0662.103 114.263.343 108.7264.637 21.187(0.769) 9.272(0.337) 24.542(0.377)
Triglycerides, mg/dl 162.3265.801 166.4668.09 140.55610.496 21.394(0.913) 22.758(0.928) 21.485(0.927)
Systolic BP, mmHg 130.3560.923 130.561.107 128.7262.22 20.336(0.849) 2.109(0.617) 21.141(0.611)
Diastolic BP, mmHg 81.7460.609 82.6660.8 79.761.39 21.064(0.374) 1.653(0.565) 22.194(0.150)
WC, cm 84.4960.48 84.4660.6 84.0661.38 0.356(0.672) 1.551(0.443) 0.140(0.896)
Adiponectin, mg/ml 13.5460.417 13.2760.516 12.8561.047 0.269(0.640) 0.420(0.758) 0.323(0.663)
rs2241766 (T45G)
Risk allele
(Genotypes) b(P)
TT TG GG T(T/G) Model 1
a Model 2
b Model 3
c
HDL-C, mg/dl 48.9461.56 49.3560.63 48.4260.73 20.159(0.763) 23.045(0.134) 0.780(0.514)
Glucose, mg/dl 109.1567.08 111.1362.23 109.3062.68 0.726(0.859) 2.949(0.748) 0.237(0.965)
Triglycerides, mg/dl 152.5613.93 164.467.32 167.5767.24 5.847(0.415) 19.839(0.239) 0.881(0.963)
Systolic BP, mmHg 135.1662.91 128.660.97 131.3460.99 23.142(0.064) 27.532(0.073) 20.2.835(0.204)
Diastolic BP, mmHg 84.4562.0 79.960.62 83.260.72 21.975(0.088) 23.805(0.142) 22.105(0.167)
WC, cm 86.8961.27 83.7660.54 85.0660.54 20.245(0.763) 22.517(0.164) 0.448(0.674)
Adiponectin, mg/ml 16.0961.38 13.1660.43 13.3960.50 20.791(0.158) 21.347(0.282) 20.902(0.222)
Data are mean 6 SEM or b(P). HDL-C indicates high-density lipoprotein cholesterol; WC, waist circumference; BP, blood pressure.
All estimates were analyzed using liner regression model, and adjustments were made for age, sex, body mass index, glucose, blood pressure, waist circumference,
triglycerides, and HDL-choleserol.
aModel 1: additive model;
bModel 2: dominant model;
cModel 3: recessive model.
doi:10.1371/journal.pone.0019999.t003
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polymorphism and cardio-metabolic disease were diverse. It has
been reported that the T allele of rs1501299 (G276T) polymor-
phism associated with increased insulin resistance and type 2
diabetes [28,29]. On the other hand, subjects carrying the G allele
of rs1501299 (G276T) polymorphism were reported to have
Table 4. Baseline characteristics of case-control designed replication study.
MetS(2) MetS(+)
HTN (2)
(n=667)
HTN (+)
(n=246)
HTN (2)
(n=240)
HTN(+)
(n=290)
Age, years 53.360.4 {{ 1 57.460.7* 56.860.6* 57.860.6*
Male, n (%) 338(50.7) 150(61) 82 (33.5) 136(47)
BMI, kg/m
2 23.160.1 { 1 23.560.2 { 1 26.460.2*{ 26.460.2*{
Waist circumference, cm 78.160.3 { 1 79.760.5 { 1 87.960.5*{ 87.960.5*{
Blood pressure, mmHg
Systolic 111.460.4 {{ 1 139.260.9* { 1 114.860.6*{ 1 141.860.9*{
Diastolic 71.560.3 {{ 1 86.460.6* { 73.260.5*{ 1 86.760.6* {
Metabolic profiles
Cholesterol, mg/dl 194.061.6 { 1 195.862.6 { 1 215.662.9*{ 214.562.5*{
HDL-C, mg/dl 46.060.7 { 1 48.660.8 { 1 35.560.5*{ 37.060.6*{
LDL-C, mg/dl 124.862.1 { 135.368.3 144.968.4* 143.367.5
Triglycerides, mg/dl 86.561.6 { 1 83.662.3 { 1 191.768.8*{ 158.963.3*{
Glucose, mg/dl 92.161.5 { 1 93.062.5 { 1 111.764.6*{ 107.564.6*{
Data are mean 6 SEM or number (%); HTN indicates hypertension; MetS, metabolic syndrome; BMI, indicates body mass index; HDL-C, high density lipoprotein
cholesterol; LDL-C, low density lipoprotein cholesterol.
*P, 0.001 vs. MetS(2) HTN(2);
{P, 0.001 vs. MetS(+) HTN(2);
{P, 0.001 vs. MetS(2) HTN(+);
1P, 0.001 vs. MetS(+) HTN(+).
doi:10.1371/journal.pone.0019999.t004
Table 5. The association of ADIPOQ variants and variable subtypes of hypertension and metabolic syndrome among study
subjects in replication study.
Trait No. of participants Genotype at rs1501299 (G276T) OR for GG+GT vs. TT (95% CI)
GG GT TT
No. of subjects
MetS (2) HTN(2)
a 667 366 (54.8) 261 (39.1) 40 (5.9) 0.72 (0.45–1.15)
MetS (2) HTN(+)
b 246 130 (52.8) 103 (41.9) 13 (5.3) 0.96 (0.52–1.78)
MetS(+) HTN(2)
c 240 133 (55.4) 95 (39.6) 12 (5) 1.03 (0.55–1.95)
MetS(+) HTN(+)
d 290 202 (69.6) 79 (27.2) 9 (3.1) 2.15 (1.1–4.3)*
Trait No. of participants Genotype at rs2241766 (T45G) OR for TT+TG vs. GG (95% CI)
TT TG GG
No of subjects
MetS (2) HTN(2)
a 667 319 (47.8) 300 (45) 48 (7.2) 1.14 (0.77–1.68)
MetS (2) HTN(+)
b 246 127 (51.6) 98 (39.8) 21 (8.5) 0.87 (0.53–1.43)
MetS(+) HTN(2)
c 240 120 (50) 101 (42.1) 19 (7.9) 0.96 (0.58–1.61)
MetS(+) HTN(+)
d 290 144 (49.7) 123 (42.4) 23 (7.9) 0.96 (0.59–1.55)
All estimates were analyzed by logistic regression model adjusted for age, gender, body mass index, blood pressure, glucose, waist circumference, triglycerides, and
HDL-cholesterol.
HTN indicates hypertension; MetS, metabolic syndrome;
*P, 0.05
aIf the presence of phenotype of MetS(2) HTN(2) compared with other remaining subjects
bIf the presence of phenotype of MetS(2) HTN(+) compared with other remaining subjects
cIf the presence of phenotype of MetS(+) HTN(2) compared with other remaining subjects
dIf the presence of phenotype of MetS(+) HTN(+) compared with other remaining subjects.
doi:10.1371/journal.pone.0019999.t005
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ventricle hypertrophy [30], providing direct evidence that the G
allele of rs1501299 (G276T) may lead to target organ damage. It is
also in accordance with our finding that ADIPOQ gene might
contribute to the genetic association with the phenotype of
presence of HTN in MetS. Future study is indicated to evaluate
the direct impacts of the G allele of rs1501299 (G276T)
polymorphism on clinical outcomes in HTN patients.
Our current study demonstrated that the SNP variant in
ADIPOQ gene could be associated with MetS including HTN
component rather than with HTN alone or with MetS excluding
HTN component, and that the former phenotype had the lowest
plasma adiponectin value, suggesting that MetS could be seen as
clusters of metabolic abnormalities, and that ADIPOQ may
selectively contribute to some clusters of MetS, especially those
with HTN. Our findings may provide the rationale for the
inconsistent association between ADIPOQ and individual MetS
parameters in previous studies, and help to clarify the previous
observations about the connections between ADIPOQ and MetS.
There are some limitations in our study. First, there was no
significant association between plasma adiponectin value and
selected ADIPOQ SNP markers. It has been noted that previous
studies focused on the association between plasma adiponectin
level and ADIPOQ gene variants were not consistent and
occasionally discrepant [20,31]. Similar to our findings, no
significant associations between plasma adiponectin level and
ADIPOQ variants rs2241766 (T45G) and rs1501299 (G276T) were
reported [20]. There are several potential reasons for the
inconsistent association between SNP and plasma adiponectin
value. First, rs1501299 (G276T) is in intron 2 of the ADIPOQ gene
and does not have a known function. It is probably a marker of
some other variant affecting adiponectin expression. Furthermore,
rs1501299 (G276T) is in a linkage disequilibrium block encom-
passing most of the ADIPOQ gene, but whether and how far such
block extends beyond the gene boundaries remain to be
determined [32]. Second, even considering the SNP markers with
ADIPOQ gene, other gene loci such as 14q13 have been reported
to affect plasma adiponectin value and play a much bigger role
[32]. Recently, GWAS for genetic markers in determining plasma
adiponectin value in Asian population reported that genetic
variants in CDH13 on chromosome 16, but not genetic variants in
the ADIPOQ gene, influence adiponectin levels in Korean
adults.[33] However, another GWAS using plasma adiponectin
as a quantitative trait demonstrated the ADIPOQ gene as the only
major gene for plasma adiponectin in Caucasian population.[23]
Racial and dietary differences between Caucasian and Asian
populations are also proposed for the differences in GWAS
findings. Furthermore, it has been indicated that in addition to
genetic effect, plasma adiponectin level may be significantly
modified by cardiovascular risk factors and life style [28].
Accordingly, the above factors may differentially modify the
association of plasma adiponectin level with ADIPOQ gene variants
in different ethnic cohorts. Third, the subjects in this cohort study
were enrolled from community a few years ago. The definite
medication information could not be identified in detail at that
time. Fourth, because of the enrollment limitation in the family-
based association study, the case number in each phenotype was
unequal, and only the subgroup of normotensive and non-MetS,
the largest subgroup, could achieve statistical power up to 91.72%
at alpha=0.05. The statistical powers in other subgroups were
around 0.6–0.7 at alpha=0.05, probably due to inadequate
number of cases. However, although the case number may give
less satisfactory power for statistics in the family-based study, the
association between the SNP variant in ADIPOQ gene and MetS
with HTN component could be replicated in another large
independent cohort, indicating a significant association. Finally,
currently selected SNP markers may be limited and inadequate to
demonstrate the genetic connection of plasma adiopnectin value.
Further larger-scale high-throughput genotyping has being carried
out to investigate the association between genetic variants and
plasma adiponectin value.
In conclusion, the present study demonstrated the association of
both plasma adiponectin level and the variants of ADIPOQ gene
with the presence of essential HTN patients with MetS, suggesting
a selective genetic linkage of adiponectin between essential HTN
and MetS. Our findings suggest that HTN and MetS might
overlap partially with each other as a specific clinical sub-
phenotype with common genetic background.
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